KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Preferred Shares: 2017

Historic Preferred Shares for Aquestive Therapeutics (AQST) over the last 1 years, with Dec 2017 value amounting to $21.9 million.

  • Aquestive Therapeutics' Preferred Shares was N/A to $21.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $21.9 million, marking a year-over-year change of. This contributed to the annual value of $21.9 million for FY2017, which is N/A change from last year.
  • Per Aquestive Therapeutics' latest filing, its Preferred Shares stood at $21.9 million for FY2017.
  • Over the past 5 years, Aquestive Therapeutics' Preferred Shares peaked at $21.9 million during FY2017, and registered a low of $21.9 million during FY2017.
  • Moreover, its 1-year median value for Preferred Shares was $21.9 million (2017), whereas its average is $21.9 million.